Survival Rates

Patients who received checkpoint blockade immunotherapy had an average survival of 12.4 months (compared to 5.2 months for those who did not receive immunotherapy), and had a four-year survival rate of 28.1 percent (compared to 11.1 percent for those who did not receive immunotherapy).

Though we do not know the survival rates following a natural approach to immune system stimulation and revival we are playing for keeps in terms of Conquering Cancer.